Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809214 | 0.92 | MCL1 (0.41) | GRIN2BMCL1KMT2ALMNA | |
| SCHEMBL23809423 | 0.91 | MCL1 (0.42) | GRIN2BMCL1KMT2APTGS2NPC1 | |
| SCHEMBL26581333 | 0.88 | GRIN2B (0.52) | GRIN2BMCL1MEN1KMT2ALMNA | |
| SCHEMBL20605074 | 0.87 | GRIN2B (0.45) | GRIN2BMCL1MEN1KMT2ALMNA | |
| SCHEMBL23809414 | 0.85 | HTR1A (0.42) | MCL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23809510 | 0.81 | GRIN2B (0.39) | GRIN2BMCL1 | |
| SCHEMBL23800639 | 0.80 | GRIN2B (0.52) | GRIN2BPTGS2 | |
| SCHEMBL26581336 | 0.79 | GRIN2B (0.50) | GRIN2BMCL1MAPTTP53 | |
| SCHEMBL20604943 | 0.78 | GRIN2B (0.43) | GRIN2BMCL1KMT2A | |
| SCHEMBL26581555 | 0.78 | MCL1 (0.46) | GRIN2BMCL1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | GRIN2B 3904/4885MCL1 1/4885MEN1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.